Scarica l'app Stockscreener
26.78
3.92%
1.01
Dopo l'orario di chiusura:
26.69
-0.09
-0.34%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$25.77
Aprire:
$25.88
Volume 24 ore:
82.93M
Relative Volume:
1.28
Capitalizzazione di mercato:
$152.26B
Reddito:
$62.58B
Utile/perdita netta:
$7.79B
Rapporto P/E:
19.76
EPS:
1.3551
Flusso di cassa netto:
$10.38B
1 W Prestazione:
+3.56%
1M Prestazione:
+6.35%
6M Prestazione:
+13.81%
1 anno Prestazione:
+3.52%
Intervallo 1D:
$25.86
$26.98
Intervallo di 1 settimana:
$25.26
$26.98
Portata 52W:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.78 | 146.52B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,107.12 | 898.12B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
234.47 | 561.61B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
217.11 | 398.83B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
118.33 | 287.52B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
152.91 | 287.55B | 54.45B | 14.42B | 17.15B | 7.333 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-02 | Ripresa | Citigroup | Neutral |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail
Pfizer Inc. (PFE): A Bull Case Theory - Insider Monkey
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop - TechStock²
Pfizer’s experimental weight loss drug shows promise in mid-stage trial - AOL.com
Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss - Finviz
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus - TechStock²
Pfizer and BioNTech Pause modRNA Shingles Ambitions - TipRanks
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Pfizer Inc. 2025 Q4ResultsEarnings Call Presentation (NYSE:PFE) 2026-02-04 - Seeking Alpha
Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript - Insider Monkey
Pfizer Stock Forecast: Trending Outlook From Street Watchers - TipRanks
Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care - Financial Times
Novo Nordisk: Pfizer weight loss drug offers credible new competition - Yahoo Finance
PFIZER INC : Gets a Neutral rating from Goldman Sachs - marketscreener.com
Pfizer Earnings: Seagen Impairment and Metsera Tolerability Data Incrementally Negative - Morningstar Canada
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs - BioSpace
Skipping the Super Bowl, Pfizer unveils new cancer campaign that still nods to sportsMM+M - Medical Marketing and Media
Pfizer channels Al Pacino’s ‘Any Given Sunday’ speech in fight against cancer - Ad Age
Adell Harriman & Carpenter Inc. Purchases 45,578 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer takes small step toward obesity market, but investors question limited trial results - Crain's New York Business
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance - BioSpace
Thrivent Financial for Lutherans Purchases 132,453 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Q4 Earnings Call Highlights - MarketBeat
Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story - Yahoo Finance
Will the Market Crash in 2026? Here's What History Says and What to Do About It - The Motley Fool
Why 2026 Could Be the Year Pfizer's Stock Finally Takes Off - Finviz
Pfizer Obesity Drug Data Triggers Sell-Off: Buy or Sell the Dip? - NAI500
Pfizer stock slides on obesity drug data, earnings; what PFE investors watch next - TechStock²
Pfizer (NYSE:PFE) Trading Down 3.3%Here's What Happened - MarketBeat
Pfizer Earnings Call: Pipeline Strength Amid COVID Reset - TipRanks
Health Care Down After Pfizer, Novo Nordisk Earnings -- Health Care Roundup - marketscreener.com
Pfizer CEO addresses growing competition in weight-loss drugs - Fox Business
Pfizer stock dips on Metsera mid-stage trial results - Axios
Pfizer Is Bullish On Obesity As It Gets Back In The Game - Citeline News & Insights
These Stocks Are Today’s Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More - Barron's
Pfizer's Metsera GLP-1 hits mark for once-monthly dosing - BioWorld MedTech
Pfizer (PFE) Exceeds 2025 Financial Targets, Focuses on Strategi - GuruFocus
Pfizer Inc (PFE) Q4 2025 Earnings Call Highlights: Strategic Acq - GuruFocus
Did Pfizer's Obesity Shot Do Well Enough To Catch Lilly? - Investor's Business Daily
Pfizer's Diversified Portfolio Supports a Narrow Moat Despite an Upcoming Patent Cliff - Morningstar
Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity - Citeline News & Insights
Data for Pfizer’s Monthly Injectable GLP-1 Drug Pave Way for Broad Phase 3 Plan in Obesity - MedCity News
Pfizer Stock Falls After Solid Earnings. What’s Troubling Wall Street. - Barron's
Pfizer stock drops after obesity-drug data, even as 2026 outlook holds - TechStock²
Pfizer weight-loss drug data raises questions about side effects, shares fall - BNN Bloomberg
Pfizer Delivers Solid 2025 Results, Reaffirms 2026 Outlook - AlphaStreet
Pfizer is at 'the end of the beginning' in entry to GLP-1s: CEO - Yahoo Finance
Tranche Update on Pfizer Inc.'s Equity Buyback Plan announced on December 14, 2018. - marketscreener.com
Pfizer: Messy Q4 Earnings Mask An Improving Business (NYSE:PFE) - Seeking Alpha
Pfizer Beats Sales Estimates on Demand for Older Drugs - Bloomberg.com
Pfizer (NYSE:PFE) Shares Gap DownWhat's Next? - MarketBeat
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.06%
6.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):